Advertisement

Effects of Etofibrate on Risk Factors of Atherosclerosis

  • T. Seifert
  • W. Schatton
Conference paper
Part of the Proceedings in Life Sciences book series (LIFE SCIENCES)

Abstract

For some time now the concept of the multifactorial genesis of atherosclerosis has been well accepted. Originally, it was based on the results of large epidemiological studies, which showed a powerful correlation between certain habits of life or metabolic or pathophysiological states, on the one hand, and the probability of contracting an atherosclerotic disease, on the other. The parameters of prognostic value were called risk factors. The 18-year follow-up of the Framingham study confirmed, among other factors; that serum cholesterol is a risk factor in the development of cardiovascular disease. In addition, different risk factors, when present at the same time, potentiate each other to an enormous risk. The coronary risk increases overproportionately with the blood cholesterol level, growing to a life-threatening danger in patients with familial homozygous hypercholesterolemia. An evaluation of the data of the Pooling Project by means of the Framingham HDL-risk-multipliers shows the incidence of fatal or nonfatal myocardial infarction to decrease in men at any concentration of total cholesterol by a factor of 2.5 as HDL-cholesterol increases from less than 40 mg dl-1 to more than 50 mg dl-1. For this reason the atherogenic index LDL-cholesterol/HDL-cholesterol beats the concentration of total cholesterol in estimating the coronary risk. Hyperlipoproteinemia is not only correlated with coronary vascular disease, but also with peripheral arterial acclusion disease (PAOD). In a group of patients with symptomatic PAOD, hyperlipoproteinemia was found in 76% of the patients, which was twice as much as in subjects without PAOD.

Keywords

Fibrinolytic Activity Plasma Viscosity Atherogenic Index Blood Cholesterol Level Fatal Myocardial Infarction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV (1981) Studio a doppio cieco sull’at-tivita terapeutica di un nuovo farmaco ipolipemizzante: L’etofibrato. Clin Ther 96:31–38Google Scholar
  2. Betz E, Hämmerle H (1986) Effect of etofibrate and its metabolites on atheromas of rabbits and on smooth muscle cell cultures. Drug Res 36:92–98Google Scholar
  3. Diehm C (1984) Carbohydrate-metabolism and fat-metabolism in normal persons and patients with peripheral arterial occlusive disease — the consequences of strenuous exercise. VASA J Vasc Dis (Suppl 13):1–61Google Scholar
  4. Ernst E (1986) Hämorheologie und zerebrale Insuffizienz. Therapiewoche 36:2514–2526Google Scholar
  5. Heinrich D, Thilo-Körner DGS, Roka L (1983) Die Bedeutung des Gefäßendothels für die Regulation der Fibrinolyse. Drug Res 33:1375–1378Google Scholar
  6. Hess H, Mietaschik A, Deichsel G (1985) Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. Lancet 1:415–419PubMedCrossRefGoogle Scholar
  7. Longenecker GL (1985) The platelets. Physiology and pharmacology. Academic Press, London New York OrlandoGoogle Scholar
  8. Lowe GDO, Drummond MM, Lorimer AR, Hutton I, Forbes CD, Prentice CRM, Barbenel JC (1980) Relation between extent of coronary artery disease and blood viscosity. Br Med J 673:674Google Scholar
  9. Pfeiffer M, Tilsner V (1978) Der Einfluß von Etofibrat auf die Plasmaviskosität bei Hyperlipoprote-inämien. Med Klin 73:60–62PubMedGoogle Scholar
  10. Schatton W, Holm E (1986) Etofibrat bei schweren diätrefraktären Fällen von Hyperlipoprotein-ämie. Fortschr Med 13:281–282Google Scholar
  11. Spöttl F, Forschauer J (1976) Influence of etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia. Atherosclerosis 25:293–301PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • T. Seifert
    • 1
  • W. Schatton
    • 2
  1. 1.Abteilung für Klinische ForschungMerz & Co.Frankfurt/MainGermany
  2. 2.Abteilung für PharmakologieMerz & Co.Frankfurt/MainGermany

Personalised recommendations